ASCO 2026 is done, and Michael and Josh have created a marathon episode for you all. This week we cover "Agents of the Present", where we summarise all the important trials with updates, overall survival and progression-free survival data that could influence your practice.

They cover immunotherapy, lifestyle interventions, pan-PI3K inhibitors, rare cancers (such as uveal melanoma), and antibody drug conjugates, to name a few. All the cancer types are covered, including genitourinary, gynaecological cancers, breast, colorectal, lung and lifestyle interventions!

Two more episodes to come!

Studies Discussed in this Episode

EV-302 Extended Follow-Up

ROSELLA (Ovarian Cancer)

RAMPART (Adjuvant RCC)

VIKTORIA-1 (HR +ve Breast Cancer)

OptimUM

OPTIMA (Breast Cancer)

Anbenitimab and Chemotherapy (HER2 +ve Breast Cancer)

TALAPRO-3 (Prostate Cancer)

GLP-1 in HR +ve Breast Cancer

Lifestyle Interventions in HR +ve Breast Cancer

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at [email protected]

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content.

Hosted on Acast. See acast.com/privacy for more information.